June 16, 2011

Center for Biotechnology
Central New York Biotechnology Research Center
Columbia University Biomedical Informatics
Cornell University Institute for Biotechnology & Life Sciences Technologies New York Academy of Sciences
New York City Bioscience Initiative
New York State Assembly
New York State Department of Health
New York Biotechnology Association
New York State Legislature
Medical Society of the State of New York
Office of Governor Anthony Cuomo


Business of Biosimilars and Biobetters

June 16, 2011

September 19-21, 2011
Seaport World Trade Center
Boston, MA
Read More


Business of Biosimilars and Biobetters

June 16, 2011

September 19-21, 2011
Seaport World Trade Center
Boston, MA
Read More


4th Annual International Partnering Conference – BioPharm America

June 16, 2011

September 7-9, 2011
Westin Boston Waterfront
Boston, MA
Read More


4th Annual International Partnering Conference – BioPharm America

June 16, 2011

September 7-9, 2011
Westin Boston Waterfront
Boston, MA
Read More


The 4th Massachusetts Life Sciences Innovation Day

June 16, 2011

June 2, 2011
Harvard Club of Boston, 374 Commonwealth Avenue
Boston, MA
Read More


Follow-on Biologics: Current Trends and Insights


June 16, 2011

March 7, 2011
Federal Reserve Bank of Boston; New England Room
Boston, MA
Read More


MassBio Federal Policy White Paper – 2009

June 16, 2011

MassBio is front and center on Capitol Hill when it comes to advocating for policies that will pave the way for innovation. We fight for the laws and regulations that will speed the development of treatments and cures for Alzheimer’s, Diabetes, HIV/AIDs and other ailments. We work for policies that will help bring those drugs to the market and make them available to all.
Read More


MassBio – Biosimilars – Our View

June 16, 2011

Drugs developed through biotechnology differ from traditional small molecule chemical drugs. They are “biologics” that are complex medicines manufactured using living organisms. Biosimilars, also known as follow-on biologics are products that are similar to, but not the same as, an innovative new drug. They are not generic drugs, which are products shown to be the same as an innovative drug and generally designated as therapeutically interchangeable.
Read More


Massachusetts Government – Life Sciences

June 16, 2011

From pharmaceuticals and medical devices to diagnostics and biotechnology, the life sciences are a cornerstone of Massachusetts’ innovation economy.  Massachusetts is a global leader in the life sciences, thanks to our world-class academic institutions and medical centers, our talented workforce, and our industry-sector leading companies.
Read More


logo logo logo